Cargando…

Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases

BACKGROUND: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined. The aim of this study was to evaluate the efficacy and toxicity of CCT. METHODS: The characteristics o...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Lipin, Bi, Nan, Ji, Zhe, Li, Junling, Wang, Jingbo, Wang, Xiaozhen, Hui, Zhouguang, Lv, Jima, Liang, Jun, Zhou, Zongmei, Wang, Yan, Yin, Weibo, Wang, Luhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609086/
https://www.ncbi.nlm.nih.gov/pubmed/26474893
http://dx.doi.org/10.1186/s12885-015-1710-2
_version_ 1782395764244217856
author Liu, Lipin
Bi, Nan
Ji, Zhe
Li, Junling
Wang, Jingbo
Wang, Xiaozhen
Hui, Zhouguang
Lv, Jima
Liang, Jun
Zhou, Zongmei
Wang, Yan
Yin, Weibo
Wang, Luhua
author_facet Liu, Lipin
Bi, Nan
Ji, Zhe
Li, Junling
Wang, Jingbo
Wang, Xiaozhen
Hui, Zhouguang
Lv, Jima
Liang, Jun
Zhou, Zongmei
Wang, Yan
Yin, Weibo
Wang, Luhua
author_sort Liu, Lipin
collection PubMed
description BACKGROUND: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined. The aim of this study was to evaluate the efficacy and toxicity of CCT. METHODS: The characteristics of LA-NSCLC patients treated with curative concurrent CRT from 2001 to 2010 were retrospectively reviewed. RESULTS: Among 203 patients, 113 (55.7 %) patients received CCT. The median number of delivered CCT was 3 and 89.4 % patients completed ≥2 cycles. The OS was significantly better for patients in the CCT group compared with that in the non-CCT group (median OS, 27 months vs. 16 months; 5-year OS, 30.4 % vs. 22.5 %; p = 0.012). The median PFS were 12 months in the CCT group and 9 months in the non-CCT group (p = 0.291). The survival advantages of CCT were significant for males (HR: 0.63; 95 % CI, 0.44 − 0.90), patients with age < 60 years (HR: 0.63; 95 % CI, 0.42 − 0.95), non-squamous histology (HR: 0.44; 95 % CI, 0.25 − 0.76), pretreatment KPS ≥ 80 (HR: 0.67; 95 % CI, 0.48 − 0.93), stage IIIb (HR: 0.64; 95 % CI, 0.43 − 0.95), stable disease (HR: 0.31; 95 % CI, 0.14 − 0.65) and radiotherapy dose ≥ 60 Gy (HR: 0.69; 95 % CI, 0.48 − 1.00). There was no significant difference between the CCT group and the non-CCT group regarding treatment-related toxicities. CONCLUSIONS: CCT might further prolong survival compared with CRT alone for LA-NSCLC without increasing treatment-related toxicities, especially for males, patients with age < 60 years, non-squamous histology, pretreatment KPS ≥ 80, stage IIIb, stable disease and radiotherapy dose ≥ 60 Gy. Large size prospective investigations that incorporate patient characteristics and treatment response are warranted to validate our findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1710-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4609086
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46090862015-10-18 Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases Liu, Lipin Bi, Nan Ji, Zhe Li, Junling Wang, Jingbo Wang, Xiaozhen Hui, Zhouguang Lv, Jima Liang, Jun Zhou, Zongmei Wang, Yan Yin, Weibo Wang, Luhua BMC Cancer Research Article BACKGROUND: For patients with locally advanced non-small-cell lung cancer (LA-NSCLC), the role of consolidation chemotherapy (CCT) following concurrent chemoradiotherapy (CRT) is partially defined. The aim of this study was to evaluate the efficacy and toxicity of CCT. METHODS: The characteristics of LA-NSCLC patients treated with curative concurrent CRT from 2001 to 2010 were retrospectively reviewed. RESULTS: Among 203 patients, 113 (55.7 %) patients received CCT. The median number of delivered CCT was 3 and 89.4 % patients completed ≥2 cycles. The OS was significantly better for patients in the CCT group compared with that in the non-CCT group (median OS, 27 months vs. 16 months; 5-year OS, 30.4 % vs. 22.5 %; p = 0.012). The median PFS were 12 months in the CCT group and 9 months in the non-CCT group (p = 0.291). The survival advantages of CCT were significant for males (HR: 0.63; 95 % CI, 0.44 − 0.90), patients with age < 60 years (HR: 0.63; 95 % CI, 0.42 − 0.95), non-squamous histology (HR: 0.44; 95 % CI, 0.25 − 0.76), pretreatment KPS ≥ 80 (HR: 0.67; 95 % CI, 0.48 − 0.93), stage IIIb (HR: 0.64; 95 % CI, 0.43 − 0.95), stable disease (HR: 0.31; 95 % CI, 0.14 − 0.65) and radiotherapy dose ≥ 60 Gy (HR: 0.69; 95 % CI, 0.48 − 1.00). There was no significant difference between the CCT group and the non-CCT group regarding treatment-related toxicities. CONCLUSIONS: CCT might further prolong survival compared with CRT alone for LA-NSCLC without increasing treatment-related toxicities, especially for males, patients with age < 60 years, non-squamous histology, pretreatment KPS ≥ 80, stage IIIb, stable disease and radiotherapy dose ≥ 60 Gy. Large size prospective investigations that incorporate patient characteristics and treatment response are warranted to validate our findings. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1710-2) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-16 /pmc/articles/PMC4609086/ /pubmed/26474893 http://dx.doi.org/10.1186/s12885-015-1710-2 Text en © Liu et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Liu, Lipin
Bi, Nan
Ji, Zhe
Li, Junling
Wang, Jingbo
Wang, Xiaozhen
Hui, Zhouguang
Lv, Jima
Liang, Jun
Zhou, Zongmei
Wang, Yan
Yin, Weibo
Wang, Luhua
Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title_full Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title_fullStr Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title_full_unstemmed Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title_short Consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
title_sort consolidation chemotherapy may improve survival for patients with locally advanced non-small-cell lung cancer receiving concurrent chemoradiotherapy - retrospective analysis of 203 cases
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609086/
https://www.ncbi.nlm.nih.gov/pubmed/26474893
http://dx.doi.org/10.1186/s12885-015-1710-2
work_keys_str_mv AT liulipin consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT binan consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT jizhe consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT lijunling consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT wangjingbo consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT wangxiaozhen consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT huizhouguang consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT lvjima consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT liangjun consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT zhouzongmei consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT wangyan consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT yinweibo consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases
AT wangluhua consolidationchemotherapymayimprovesurvivalforpatientswithlocallyadvancednonsmallcelllungcancerreceivingconcurrentchemoradiotherapyretrospectiveanalysisof203cases